New biosimilar guidance from EMA allows non-EU comparator
This article was originally published in Scrip
The revised version of the European Medicines Agency's general guideline on biosimilar medicines has now been published, complete with a number of changes from the original, including the possibility of using a non-EU comparator drug in order to avoid unnecessary clinical testing, and of extrapolating indications in certain cases without clinical data.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.